Loading data for XFOR — first visit, this takes a few seconds.

알림

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · 실시간 가격 · USD

4.64

+0.47 (11.27%)

종가 기준: Aug 19, 2026, 3:20 PM

11.27% (1D)

데이터 없음

매수호가	4.62
시가총액	418.89M
매출 (ttm)	15.85M
순이익 (ttm)	-90.14M
베타	0.39
EPS (ttm)	1.43
P/E (ttm)	2.95
선행 P/E	-5.6
P/B (ttm)	2.61
P/S (ttm)	26.43
Earnings Date	Nov 5, 2026

매도호가	5.5
거래량	1,590,946
평균 거래량 (20일)	691,472
시가	4.26
전일 종가	4.17
일중 범위	4.21 - 4.82
52주 범위	1.35 - 4.83
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

XFOR 소개

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 16, 2017

직원 수 45

상장 거래소 NasdaqCM

티커 XFOR

웹사이트 https://www.x4pharma.com

전체 기업 정보

재무 실적

2025년 X4 Pharmaceuticals의 매출은 35.11M로, 전년 2.56M 대비 1,273.21% 증가했습니다. 순이익은 -79.2M로, 111.48% 증가했습니다.

재무제표

어닝 서프라이즈

X4 Pharmaceuticals가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $8.81M 예상치 하회 $0, 및 346.33% 전년 대비 성장.

EPS -0.13 예상치 상회 0.05, 및 96.25% 전년 대비 성장.

다음 실적 발표

X4 Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3개월 전 · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

3개월 전 · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

3개월 전 · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 페이지 중 1

X4 Pharmaceuticals Inc. (XFOR)